GT Biopharma (NASDAQ:GTBP) Stock Price Down 8.8% – Should You Sell?

GT Biopharma, Inc. (NASDAQ:GTBP) traded down 8.8% on Monday . The company traded as low as $0.3730 and last traded at $0.3877. Approximately 1,719,132 shares changed hands during trading, an increase of 45% from the average session volume of 1,181,820 shares. The stock had previously closed at $0.4250.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. Wall Street Zen raised GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

GT Biopharma Trading Down 6.8%

The firm has a market capitalization of $15.25 million, a P/E ratio of -0.05 and a beta of 0.84. The business’s 50 day simple moving average is $0.43 and its two-hundred day simple moving average is $0.49.

GT Biopharma (NASDAQ:GTBP) last issued its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Analysts predict that GT Biopharma, Inc. will post -0.34 EPS for the current fiscal year.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in GT Biopharma, Inc. (NASDAQ:GTBP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned about 0.47% of GT Biopharma at the end of the most recent reporting period. Institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).